|Bid||78.33 x 1200|
|Ask||78.43 x 1100|
|Day's Range||77.98 - 79.06|
|52 Week Range||68.44 - 84.56|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||35.67|
|Forward Dividend & Yield||2.60 (3.32%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MRKLearn more
The plan to roll out Merck & Co's promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the line, international health groups say. Merck on Oct 11 applied for U.S. emergency clearance of the first pill for COVID-19 after it cut hospitalizations and deaths by 50% in a large clinical trial. The medicine, made with Ridgeback Biotherapeutics, could gain authorization as soon as December.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics have already made a big splash with positive results for their COVID-19 pill. However, there are are other companies nipping at their heels. In this Motley Fool Live video recorded on Oct.
Pfizer (NYSE: PFE) launched the best-selling vaccine Comirnaty with the help of its partner, BioNTech. Merck (NYSE: MRK) is likely to soon have the first COVID-19 pill on the market. Pfizer has delivered greater stock gains than Merck since the beginning of the pandemic.